Podcasts about Genomics

In 1987, Mary P. Lovato, a member of Kewa Pueblo in New Mexico, was diagnosed with acute leukemia. To receive a bone marrow transplant, she had to travel more than 800 miles from home because specialized cancer care was unavailable through the Indian Health Service. When she returned, she discovered another obstacle: many in her community feared cancer so deeply that they avoided speaking about it altogether.This episode examines how cancer survivorship exposed profound inequities in the American healthcare system. Long before health equity became a national priority, advocates from underserved communities were confronting disparities rooted in geography, poverty, racism, language, underfunded healthcare systems, and historical mistrust of medical institutions. Their work demonstrated that scientific advances alone cannot improve survival if patients cannot reach, afford, or trust the care available to them.The story follows pioneers including Mary P. Lovato, who built the first national Native-led cancer support and education program for Indigenous communities, and Maimah Karmo, founder of the Tigerlily Foundation, whose breast cancer diagnosis inspired a movement to improve early detection, clinical trial participation, and representation for Black women. Their advocacy challenged longstanding barriers to culturally competent care while highlighting persistent inequities in access to screening, fertility preservation, navigation, and innovative treatments.The episode also explores why diversity in clinical research matters. For decades, many cancer clinical trials disproportionately enrolled White patients, limiting both access to promising therapies and the scientific understanding of how treatments perform across different populations. Researchers, patient advocates, and community leaders responded by redesigning outreach, improving patient navigation, reducing logistical barriers, and insisting that affected communities help shape the research itself.Cancer survivorship cannot be measured solely by scientific breakthroughs. It also depends on whether every patient has a meaningful opportunity to benefit from them. The pursuit of health equity remains one of the defining challenges and enduring responsibilities of modern oncology.RELATED LINKSNational Cancer Institute | Cancer Health Disparities⁠Indian Health Service⁠Tigerlily Foundation⁠National Cancer Institute | Cancer Clinical Trials⁠American Indian Cancer Foundation⁠Abramson Cancer Center | University of Pennsylvania⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr. Boris Vinatzer, 2026 APS Fellow and Professor of Microbial Genetics and Genomics in the School of Plant and Environmental Sciences at Virginia Tech in Blacksburg, Virginia joins host Matt Kasson to discuss his career working on plant biotechnology and plant pathogenic bacteria with an emphasis on Pseudomonas syringae and Rolstonia solanacearum. He also talks about his work on ice nucleation activity in bacteria and fungi and genome-based approaches for plant disease diagnostics including multi-locus sequence analysis for species level identification of plant pathogenic bacteria. show notes The full transcript for this episode can be found here: Dr. Boris Vinatzer's Virginia Tech faculty webpage: https://spes.vt.edu/faculty-staff/faculty/vinatzer-boris.html Dr. Boris Vinatzer's Google Scholar profile: https://scholar.google.com/citations?user=STcUUYcAAAAJ&hl=en Dr. Boris Vinatzer's 2026 APS Fellow Profile: https://www.apsnet.org/members/give-awards/Pages/awardees.aspx This episode is produced by Association Briefings.Special Guest: Boris Vinatzer.

Send us Fan MailHow genomics is used to study what makes a human brain, and how genetically damaged neurons get removed.TOPICS DISCUSSED:Scale & Size: A human brain is about three times a chimpanzee brain by mass, but the larger change is extra association cortex and extra upper-layer circuits that talk mostly to other cortex.When Development Ends: Most cortical neurons are born before birth. Myelin and other glia keep forming into the twenties. Synapses keep changing after that.Broken Genomes Get Edited: Walsh describes forthcoming work in which ~25–30% of late-fetal cortical neurons carry genetic defects, falling to ~5% by birth, with smaller defects still being removed through adult life.Regulation vs. New Genes: Humans and mice both have ~20,000 genes. Most human-specific change is in when and where those genes turn on, not in inventing new proteins.Human Accelerated Regions: About half of HARs involve the brain. Rare mutations in them show up more often in kids with intellectual disability and autism.ASPM & Microcephaly: Loss of one conserved cell-division gene can shrink a human brain toward chimpanzee volume and shape. The same knockout barely shrinks a mouse.Heritability of Genetic Disorders: Autism is highly heritable in twin studies. A whole-genome test today still finds a specific cause in only about a quarter to a third of kids.Support the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.

In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To Cancer⁠Katie Couric Media⁠Dempsey Center⁠American Association for Cancer Research⁠National Cancer Institute⁠Dana-Farber Cancer Institute | Adult Survivorship Program⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer Program⁠Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer⁠American Society of Clinical Oncology | Fertility Preservation Guidelines⁠Stupid Cancer⁠Livestrong Foundation⁠Journal of Adolescent and Young Adult Oncology⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Have you heard about the radioactive wolves in Chernobyl? Or the latest gene-editing tech that's curing rare diseases? Or that male birth control might be on the horizon? No?!Well, get ready, because while we've been busy living our lives, genomics has been moving – fast! Things that once read like science fiction are moving on over to the non-fiction section.This season on Nice Genes!, join Dr. Kaylee Byers as she engages in some big genomics breakthroughs – from personalized cancer treatments, to how our bodies react in space, to how animals adapt to the most extreme environments, and whether we can actually change how we age.It's a whole new gene-eration (if you will) of discoveries that you won't want to miss!New episodes every two weeks, starting September 8th. Make sure you follow Nice Genes! so you don't miss an episode!

In 2006, the Institute of Medicine published From Cancer Patient to Cancer Survivor: Lost in Transition, concluding that millions of Americans were surviving cancer only to find themselves navigating a healthcare system unprepared for life after treatment. The report challenged oncology to recognize that curing cancer was not the end of care, but the beginning of survivorship.This episode explores how the growing cancer survivorship movement exposed the long-term consequences of cancer treatment that medicine had largely overlooked. As survival rates improved following the National Cancer Act of 1971, millions of survivors faced chronic fatigue, neuropathy, infertility, cognitive impairment, financial hardship, employment discrimination, anxiety, depression, and post-traumatic stress. These were not rare complications. They became defining features of survivorship for many patients.Drawing on the work of oncologist Dr. Patricia Ganz, survivor advocate Ellen Stovall, and researchers, clinicians, and survivors across the country, the episode examines how survivorship research expanded beyond recurrence and mortality to include quality of life, psychosocial care, rehabilitation, and long-term follow-up. Their efforts helped establish survivorship care plans, multidisciplinary survivorship clinics, and a broader understanding that cancer affects every aspect of a person's life long after treatment ends.The episode also confronts persistent inequities in survivorship care. Insurance coverage often ends when treatment stops, supportive services remain inconsistent, financial toxicity continues to drive medical hardship, and racial, geographic, and socioeconomic disparities still influence who receives comprehensive follow-up care. For many survivors, finishing treatment simply marks the beginning of another struggle.Modern oncology increasingly recognizes that surviving cancer is measured by more than years of life. It is also measured by quality of life, dignity, access to care, and the ability to rebuild a future after treatment. That evolution remains one of the most significant legacies of the cancer survivorship movement.RELATED LINKSNational Academy of Medicine | ⁠From Cancer Patient to Cancer Survivor: Lost in Transition⁠National Cancer Institute Office of Cancer Survivorship⁠American Society of Clinical Oncology | Survivorship Compendium⁠CancerCare⁠HopeWell Cancer Support⁠National Coalition for Cancer Survivorship⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Twenty-five years ago, sequencing the human genome seemed poised to usher in an era of personalized medicine. Dr. Euan Ashley helped turn that promise into an actual clinical experiment, leading one of the first efforts to interpret an entire human genome in the context of a real patient's health. The challenge quickly became apparent: medicine could suddenly generate billions of data points about one person, but making sense of them was painfully slow.That history feels newly relevant. Ashley recently gave an AI system his own 15-year-old genome data and watched it reproduce most of an analysis that had originally required months of work by a team, in about 30 minutes. Meanwhile, genomics is being joined by wearables, multi-omics, and other technologies capable of tracking far more of our biology over time.In this episode of NextLevel, we use the genome revolution as a case study for what happens when our ability to measure the body advances faster than our ability to interpret and use the information. The next leap in personalized medicine may depend less on collecting another mountain of data than on building the tools, reference datasets, and healthcare systems capable of turning that information into decisions.Free course: Improve your metabolic healthGet our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠

In 1967, breast surgeon Dr. Harold P. Freeman arrived at Harlem Hospital expecting to treat cancer. Instead, he confronted a healthcare system where poverty, racism, lack of insurance, and institutional barriers often determined who lived long enough to receive treatment. Patients frequently arrived with advanced disease, not because medicine lacked answers, but because access to care had failed them.This episode explores how cancer survivorship expanded beyond medical breakthroughs to include healthcare access, health equity, and organized advocacy. Building on the early work of the National Coalition for Cancer Survivorship (NCCS), it examines the recognition that surviving cancer depended not only on research, but also on whether patients could navigate a fragmented healthcare system.Freeman responded by creating one of the nation's first patient navigation programs at Harlem Hospital in 1990. Community-based navigators helped patients overcome practical barriers including insurance, transportation, appointments, communication, and fear. The model dramatically improved timely diagnosis and treatment, increased breast cancer survival in Harlem, and ultimately inspired the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005, establishing navigation as a cornerstone of modern oncology care.The episode also follows cancer survivor Ellen Stovall, whose leadership transformed survivorship into a national policy movement. Through the NCCS, she united advocates across cancer types, fought for insurance protections, expanded access to clinical trials, helped shape the creation of the Office of Cancer Survivorship at the National Cancer Institute, and organized the landmark 1998 National March for Cancer Survivorship in Washington, D.C. Her work reframed survivorship as a public policy issue rather than a personal experience.Together, Freeman and Stovall demonstrated that scientific progress alone could not eliminate disparities in cancer outcomes. Their work established two enduring principles that continue to shape oncology today: patients need someone to help them navigate care, and survivors must have a voice in the policies that govern it. Modern cancer survivorship depends on both.RELATED LINKSNational Coalition for Cancer Survivorship⁠Harold P. Freeman Patient Navigation Institute⁠National Cancer Institute Office of Cancer Survivorship⁠Patient Navigator Outreach and Chronic Disease Prevention Act of 2005⁠American Cancer Society⁠Tuskegee Study Timeline | Centers for Disease Control and Prevention⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to a very, very, very special bonus episode of Out of Patients, and one unlike anything published on this feed before. For nearly 20 years, Matthew Zachary has handed these microphones to patients, caregivers, doctors, advocates, troublemakers, and people with something worth saying. This time, he handed them to his daughter. Hannah Greenzweig grew up around this show, and now she has commandeered the studio with 3 of her wonderfully creative high school friends to talk about something they built entirely themselves. There is an enormous amount of Dad Pride baked into this episode, along with the strange and wonderful realization that sometimes your kid grows up, takes your chair, takes your microphone, and produces a better show without you.Hannah Greenzweig, Michael Aidinov, Gwendolyn Baldini, and Astronomy are student artists from the Roundabout Youth Ensemble at James Madison High School in Brooklyn. Working alongside teaching artists from Roundabout Theatre Company, they spent a school year creating an original play from the ground up, writing every scene, developing every character, and producing the performance themselves.Instead of discussing a Broadway production, they dissect one they invented.Their play, Subject Matter, began with a room full of improbable ideas. Murderous bounce houses, pirate family sagas, underwater adventures, courtroom dance battles, and birthday parties at math museums all competed before the group settled on an absurd rivalry between New York's fictional History Museum and Math Museum. From there, they built a fully staged comedy about institutional competition, sabotage, oversized personalities, and the unexpected discovery that history and mathematics need each other more than either side wants to admit.The conversation pulls back the curtain on a creative process most audiences never see. The students explain how scenes evolved through constant rewrites, how characters emerged from improvisation, how costumes came together with last minute ingenuity, and how rehearsals often collapsed into uncontrollable laughter. They recount cutting favorite ideas, solving production problems with limited resources, and trusting each other enough to keep rewriting until the story worked.The episode also captures something harder to script: teenagers speaking honestly about collaboration without adults translating their experience. They celebrate classmates who stepped into unexpected roles, teachers who quietly held the production together, and the strange joy of creating something that exists only because everyone showed up.It is a conversation about theater, friendship, education, creativity, and what happens when 4 young artists get the microphones and the adults get out of the way.RELATED LINKSRoundabout Theatre CompanyRoundabout Youth EnsembleJames Madison High SchoolFEEDBACKLike this bonus episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a pro when it comes to the sort of target validation work central to the field today. Now, as RGC continues the massive expansion of its genetic database, the center’s unique ability to interpret that trove of data could give it an edge in the age of AI-powered drug development. In this week’s episode of "The Top Line," Fierce’s Fraiser Kansteiner sits down with Andy Deubler, chief business and administrative officer at Regeneron Genetics Center, to discuss the role RGC plays in the larger Regeneron model, as well as where the center could be headed as drug development pushes into new technological frontiers. Aside from the data interpretation advantage RGC believes it holds in the AI era, Deubler also discusses how the unit’s ongoing genetic research has helped deliver recent breakthroughs like the hearing loss gene therapy Otarmeni. To learn more about the topics in this episode: Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval J. Craig Venter launches genomics startup designed to boost diagnostic insights Genomics inks partnership deal with Greywolf to assess gene datasets How a new tool for large-scale gene editing could power novel genetic medicines In global life sciences, insight isn’t the problem—execution is. Disconnected dashboards, siloed teams and fragmented workflows make it harder to act—consistently, compliantly and at scale. ZAIDYN by ZS closes that gap. ZAIDYN is the Life Sciences Intelligence Platform that embeds intelligence in the flow of work, based on domain expertise and agentic AI across commercial, medical, patient and content work. Trusted by more than 150 life sciences organizations across over 100 countries, ZAIDYN is built for global scale, regulatory compliance and trusted AI—so teams act together across brands, markets and channels. ZAIDYN. Move beyond reporting to intelligent action. Learn more at ZAIDYN.aiSee omnystudio.com/listener for privacy information.

A man is struck by a car on the streets of Los Angeles. In the emergency department, a CT scan ordered to look for traumatic injuries reveals something nobody expected: a mass in his colon. Days later, sitting across from Dr. Belinda Waltman, he calls the accident “a blessing in disguise.” Then he changes the subject. He is less worried about cancer than about whether he can afford to miss another day of work. In this season finale of Standard Deviation, host Dr. Oliver Bogler explores what happens when biomedical science collides with the realities of the healthcare safety net. Dr. Waltman, a primary care physician in Los Angeles County, specializes in expedited cancer workups for uninsured and underinsured patients. Every diagnosis arrives carrying another set of questions about housing, transportation, food insecurity, wages, and survival that rarely appear in medical records or scientific literature. For years, Waltman carried those stories without knowing how to bring them into the academic record. As a full-time clinician without a research lab, grant funding, or publication pipeline, she faced barriers familiar to many working scientists and physicians whose most important observations happen outside traditional research settings. With support from the Life Science Editors Foundation's JEDI program, those experiences became The Margins Matter, a narrative medicine essay published in JAMA that argues the social realities surrounding cancer care are not background details. They are part of the disease itself. Bogler traces how editorial mentorship transformed lived clinical experience into published scholarship while asking a larger question about who gets to shape the scientific record. The conversation examines cancer care, Medicaid, health-related social needs, medical publishing, and the structural incentives that determine which stories become evidence and which disappear from view.The result is a conversation about documentation, visibility, and why the margins of medicine often determine who survives long enough to benefit from its advances.RELATED LINKSDr. Belinda Waltman⁠The Margins Matter | JAMA⁠The Margins Matter | PubMed⁠Life Science Editors Foundation⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 1986, 23 survivors, physicians, nurses, attorneys, and community organizers gathered in Albuquerque, New Mexico, for a weekend that would permanently change the language and politics of cancer. Working late into the night, they debated not only strategy, but identity, ultimately declaring that from the moment of diagnosis, every person with cancer is a survivor.This episode traces the social and political forces that gave birth to the modern cancer survivorship movement. As advances in early detection and treatment allowed more people to live beyond cancer, survivors discovered that finishing treatment did not mean returning to normal life. Many faced employment discrimination, loss of insurance, social stigma, infertility, chronic health complications, and a healthcare system that viewed survival as the end of care rather than the beginning of a new chapter.Against the backdrop of the civil rights, disability rights, and community health movements of the 1960s and 1970s, physicians, activists, and survivors challenged medicine's paternalistic culture and demanded a greater voice in decisions affecting their lives. Central to this story are physician and survivor Dr. Fitzhugh Mullan, whose landmark 1985 essay, Seasons of Survival, redefined survivorship as a lifelong continuum, and community organizer Katherine Logan, whose determination united dozens of grassroots organizations into what became the National Coalition for Cancer Survivorship.The coalition's founding established principles that continue to shape oncology today. Survivors were no longer defined solely by disease or treatment outcomes. Their experiences became evidence. Their voices became essential to clinical research, healthcare policy, and patient advocacy. By redefining survivorship as an ongoing experience rather than a destination, the movement challenged medicine to recognize the lasting physical, emotional, financial, and social consequences of cancer.The ideas forged during that weekend in Albuquerque became the foundation of modern cancer survivorship. Nearly 40 years later, the coalition's defining principle, that survivorship begins at diagnosis, continues to influence cancer care, research, policy, and the way millions of people understand life after cancer.RELATED LINKSNational Coalition for Cancer Survivorship⁠National Cancer Institute Office of Cancer Survivorship⁠The New England Journal of Medicine⁠Americans with Disabilities Act (ADA.gov)⁠Library of Congress | Civil Rights History Project⁠White Coat, Clenched Fist by Fitzhugh Mullan⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On Your World of Creativity, we explore how innovators, entrepreneurs, artists, scientists, and thought leaders transform ideas into impact.Today's guest has spent three decades helping some of the world's most sophisticated science and healthcare companies answer a deceptively simple question:How do you persuade people who pride themselves on not being persuaded?Hamid Ghanadan is the founder and CEO of LINUS, a commercial strategy consultancy serving life science and healthcare innovators. A former biochemist turned strategist, Hamid has guided organizations including Twist Bioscience, Thermo Fisher Scientific, and 10x Genomics through product launches, market development, and growth initiatives.His new book, Not Buying It: The Art of Selling to Scientists, Doctors, and Other Professional Skeptics, challenges conventional thinking by arguing that even the most technical buying decisions are ultimately driven by psychology, empathy, and human behavior—not just data.Hamid 's WebsiteHamid on YouTubeHamid LinkedIn: https://www.linkedin.com/in/hghanadan/Let's explore creativity, persuasion, science, and what it takes to influence skeptical minds.Guest BioHamid Ghanadan is the Founder and CEO of LINUS, a commercial strategy consultancy focused on life sciences, healthcare, diagnostics, medical devices, and biotechnology.Originally trained as a biochemist, Hamid became fascinated with a question that would shape his entire career:How do scientists make decisions?That curiosity led him from the laboratory into marketing, strategy, and behavioral psychology. Over the past 30 years, he has developed what he calls an Insights-Led Commercial Strategy, helping science and healthcare organizations better understand customer decision-making and create meaningful demand.His new book, Not Buying It, explores how technical professionals evaluate information, why traditional marketing often fails with scientific audiences, and how empathy becomes a competitive advantage in high-stakes commercial environments.1: From Biochemist to Behavioral StrategistHamid, one of the stories I found fascinating is that your career began in a biochemistry laboratory.You describe an early encounter watching a salesperson struggle to connect with scientists, which sparked a question that changed your professional trajectory: How do you sell to such a skeptical audience? What was it about that moment that stayed with you, and how did it eventually lead you from science into strategy?2: The Psychology Behind Technical DecisionsOne of the central themes of your book is that commercial strategy is fundamentally a game of psychology. That can sound counterintuitive in industries built on evidence, data, peer review, and rigorous analysis. Yet you argue that scientists, doctors, engineers, and other technical professionals are still human beings first. What do most companies misunderstand about how highly educated professionals actually make decisions? Why isn't more data necessarily more persuasive?3: The Soul of the BrandLet's apply my favorite framework—the Soul of the Brand. Thinking about LINUS:What is your focus?What work are you really doing?Who are you serving?What gives you credibility?What industry assumptions are you challenging?And what larger mission drives the organization?4: Persuasion, Creativity, and the Age of AIIn the book, you make an interesting observation. AI is making it easier than ever to create content, automate outreach, and scale communications. But you suggest that simply producing more content creates more noise—not more influence. As someone who studies persuasion and decision-making, what concerns you most about how organizations are currently using AI? What human skills become more valuable in an AI-enabled world?5: Unlocking Influence Through EmpathyOne of the ideas that really resonated with me is your belief that the key ingredient of an effective strategy is a unique insight into audience psychology—and that finding that insight requires empathy. For leaders, marketers, entrepreneurs, healthcare innovators, and creative professionals listening today: How can they become better observers of human behavior and uncover those insights that others miss?If you enjoyed today's episode, please subscribe, rate, and review the podcast.

The scientific world was rocked last month, when the case of a six-year-old girl who died in China, surfaced. The child was believed to have Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder caused by a mutation in the CHD3 gene. The condition affects intellectual development, but its severity varies widely. The girl's parents sought an experimental treatment led by neuroscientist Zilong Qiu at the Shanghai Jiao Tong University. What happened then was the child underwent base editing therapy, a specialised form of gene editing therapy. The therapy was directed at her brain to correct a genetic mutation in her brain cells. The parents are believed to have financed much of the therapy's development. Within days of the therapy, the child developed a fever and kidney damage, and died a week later. The case has thrown up a number of issues: why was an experimental treatment such as this allowed to go forward even after animal testing had reportedly found dangerous side effects? How much treatment of this sort should be allowed when its effects are still not fully understood? Are there gaps in scientific regulatory mechanisms that need to be fixed? Should families of patients be financially supporting such treatments? And finally, what does this say about our treatment of persons with disabilities? Guest: Dr. Debojyoti Chakraborty, Senior Principal Scientist, CSIR Institute of Genomics and Integrative Biology, New Delhi Host: Zubeda Hamid Producer: Jude Weston Learn more about your ad choices. Visit megaphone.fm/adchoices

What's the difference between a sheep that looks "right" and a sheep that breeds "right"? Jonno Hicks from Hannaton Poll Merinos and White Suffolks, reckons he's finally found the answer.In this week's episode, Jonno talks through his shift from visual assessment to genomics and data-driven breeding, and why the first years weren't the easiest- despite employing a "guy in New Zealand he heard on a podcast". At Hannaton, they now record fleece attributes, carcass traits, structural traits and much more, and make the most of that data by using genomics and neXtgen Agri indices to balance progress across all of them. Tune in to hear a great yarn between two people who spend way too much time thinking about sheep genetics.Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, Heiniger Australia and New Zealand, and ProWay Livestock Equipment. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out the MSD range HERECheck out Allflex products HERECheck out Heiniger's product range HERECheck out ProWay's product range HERE

"A good way of thinking about this is this is the survival of the fittest clone. There could be a portion of a cancer that naturally has some resistance or ability to survive a particular drug. And over time, as the other cells around it are dying off, that particular clone is able to replicate and continue to survive in the face of that drug therapy and eventually take over as being the fittest clone. At that point, we're often seeing disease progression," Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about resistance pathways.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 30 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by August 7, 2027. Roman has served on advisory boards for Genetech, Pfizer, Regeneron, and Daiichi Sankyo and received honoraria payments from Pharmacy Times and Decera for faculty lectures. These financial relationships have been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge related to resistance pathways in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 423: Pharmacology 101: Interaction Pathways Episode 406: Drug Resistance Biomarkers and Their Impact on Cancer Treatment Choices ONS Voice articles: Predictive and Diagnostic Biomarkers Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance ONS book: Guide to Cancer Immunotherapy (second edition) Genomics and Precision Oncology Learning Library ONS Biomarker Database Pharmacogenomics Huddle Card CancerQuest: Cancer Drug Resistance National Comprehensive Cancer Network OncoKB.org Research To Practice To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "As we look at drug resistance, this is the concept that cancer cells are no longer able to respond to a cancer treatment. The downstream of this is that we could end up with progression of the disease and need to look at alternative therapies that may be beneficial for the patient. This is unfortunately a very common phenomenon. Drug resistance is a major cause of treatment failure and poor patient outcomes with treatments. Unfortunately, this is an issue we see that increases over time on treatment." TS 2:29 "Genetics play a really big role in drug resistance. We know that drug resistance can be due to different things. It could be epigenetics. It could be the tumor microenvironment factors. But genetics often play a very big role in resistance pathways. It's generally considered to be a critical contributor to resistance, particularly in the way of acquired variants to drug targets or amplifications of certain oncogenes that can lead cancers to have progression. A well-known genetic alteration is the BRCA1/BRCA2 variant that helps to make the cancer more efficient at fixing DNA damage. So we're trying to get DNA damage with chemotherapy, and this particular variant helps at fixing that damage to allow the cancer to progress. So that is one genetic variant we see that plays a big role in a number of different cancers." TS 4:51 "These pathways are not mutually exclusive. Oftentimes we have multiple resistance pathways involved. I think it's important to understand some of those individually, but kind of thinking about this as we might be facing multiple resistance pathways. ... We can see resistance mechanisms that vary based on the type of treatment we use, for example, traditional cytotoxic chemotherapy. We may be more likely to see some resistance mechanisms that are working at DNA: repairing broken DNA or working on those efflux pumps that are being used to push chemotherapy out of cells. If we're talking more about the targeted therapies such as tyrosine kinase inhibitors or monoclonal antibodies, we may be more likely to see resistance mechanisms that are what we discussed with that drug target alteration: changing the way that the target agents are able to bind to the tumor cells to activate or inactivate pathways so we may see some changes there." TS 12:39 "One way to overcome this and to help to decrease the resistance from developing is using combination therapy: drugs that are targeting different pathways at once or potentially using combinations with things like chemotherapy in addition to immunotherapy. In this way, as we're getting these different targets, we can hopefully decrease the mechanism of resistance that may be developing." TS 14:48 "Biomarker testing is an incredibly important part of our practice. In many situations now, we are getting upfront, comprehensive biomarker testing to identify whether the patient may have any of those intrinsic or primary resistance mechanisms that might make it so a patient is never going to respond to a particular type of treatment. And in that case, we can spare the patient from the potential toxicities of that treatment if we don't think that there's going to be benefit there. So I think that that has become a really important way that we can tailor patients for understanding what treatments are going to be more effective. And then after that, there's usually additional biomarker testing that may be warranted at the time of progression in certain types of cancer. And that really helps us to understand that acquired resistance that might be developing." TS 17:32 "Nurses are really helpful with filling in the gaps and bringing back patient concerns that might be shared with them. And these might be early signs of progression. Better understanding how our patients are feeling and what's going on with them may help us to identify a patient that we need to do some additional testing for to understand whether there is drug resistance ongoing and potential progression of disease." TS 21:52

In 1971, President Richard Nixon signed the National Cancer Act, transforming cancer research with an unprecedented federal investment and launching what became known as the War on Cancer. The legislation did not emerge from scientific discovery alone. It was the culmination of decades of relentless advocacy by researchers, philanthropists, journalists, and patients who believed cancer demanded the same national commitment that had put astronauts on the Moon.This episode traces the origins of the cancer survivorship movement by returning to a time when cancer was rarely discussed in public, many physicians withheld diagnoses from their patients, and surgery offered few lasting cures. It follows the pioneering work of pathologist Dr. Sidney Farber, whose early chemotherapy research challenged conventional thinking, and Mary Lasker, whose political strategy, fundraising, and public campaigns helped transform cancer from a private tragedy into a national public health priority. Together, they built the coalition that reshaped federal support for oncology research and forever changed the relationship between science, government, and the American public.The story then turns to journalist and breast cancer survivor Rose Kushner, whose refusal to accept the standard one-step radical mastectomy challenged nearly a century of surgical dogma. Working alongside surgeon Dr. Bernard Fisher, Kushner helped bring evidence-based medicine to breast cancer treatment through randomized clinical trials that demonstrated less invasive surgery could achieve equivalent outcomes. Their efforts changed clinical practice, strengthened informed consent, and helped establish the principle that patients should participate in decisions about their own care.The breakthroughs explored in this episode extended far beyond new treatments. They redefined the role of patients in medicine, accelerated clinical research, and laid the foundation for modern cancer survivorship. The movement that followed would not simply help more people live longer. It would change what surviving cancer meant.RELATED LINKSNational Cancer Institute⁠National Cancer Act of 1971⁠American Cancer Society⁠Dana-Farber Cancer Institute⁠National Library of Medicine⁠The New England Journal of Medicine⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if we could measure the human body the way engineers monitor a jet engine?For nearly two decades, Stanford geneticist Dr. Michael Snyder has been trying exactly that. By continuously tracking everything he could possibly track in his body—genome sequencing, metabolites, wearable data, whole-body imaging—he has turned himself (and ~100 study subjects) into one of the world's largest experiments in continuous health measurement.The point wasn't mindless biohacking. It was to answer a question: Are there clinically useful signals in all that data?This conversation suggests the answer is yes. Snyder's experience and that of dozens of his study subjects offer some of the first real evidence that continuous measurement intelligently analyzed can reveal that you're getting sick before you have symptoms, help find solutions to medical conditions that work for your unique biology, and help you refocus on prevention of disease rather than management.Free course: Improve your metabolic healthGet our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: ⁠⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠

In the final episode, Veeru Kasivisvanathan discusses the future of prostate cancer diagnosis, including AI-assisted MRI interpretation, genomic risk prediction, polygenic risk scores, and the opportunities and challenges of population screening. Discover how precision technologies could reshape prostate cancer care over the next decade. Timestamps: 00:57 – AI and MRI 02:25 – PARADIGM study 02:51 – Large-scale MRI screening 04:56 – Genomics and polygenic risk scores 06:45 – Future optimism of prostate cancer

BUFFALO, NY — August 6, 2026 — A new #research perspective was #published in Volume 18 of Aging on July 24, 2026, titled “A brief history of the hyperfunction theory of aging and future directions.” The article was written by João Pedro de Magalhães from the Genomics of Ageing and Rejuvenation Lab, Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, United Kingdom. Rather than presenting new experimental findings, the perspective examines the historical development of the hyperfunction theory of aging, reviews evidence supporting programmatic mechanisms of aging, and discusses future directions for understanding why organisms age and how aging might eventually be modified. For decades, most aging research has been dominated by the idea that aging results primarily from the gradual accumulation of molecular damage, including DNA damage, oxidative stress, mitochondrial dysfunction, and protein deterioration. In contrast, the hyperfunction theory proposes that aging is driven largely by developmental and growth programs that continue operating beyond their beneficial period. Rather than being intentionally programmed, aging is viewed as a consequence of biological pathways that promote growth and reproduction early in life but become harmful when they continue later in adulthood. The perspective traces the historical roots of these ideas from early theories proposed in the nineteenth century through Clive McCay's pioneering caloric restriction experiments and George Williams' concept of antagonistic pleiotropy. Particular attention is given to the contributions of the late Mikhail Blagosklonny, whose hyperfunction theory proposed that aging results from “quasi-programs”—developmental processes that fail to switch off after their normal biological role has ended. The author argues that this framework provides a mechanistic explanation linking evolutionary theory with many biological features of aging. Full press release - https://www.aging-us.com/news-room/hyperfunction-theory-offers-a-new-perspective-on-why-we-age Paper DOI - https://doi.org/10.18632/aging.206403 Corresponding author - João Pedro de Magalhães - jp@senescence.info Abstract video - https://www.youtube.com/watch?v=VwC6aJoUUQo Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206403 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, antagonistic pleiotropy, longevity, programmatic aging, quasi-program To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Imagine you wanted to get a general idea of what people are eating in a given community. You could look at grocery store sales, or do surveys, but neither can capture a complete picture.  Microbiome researcher Lawrence David and his lab look to another source of data: genetic material in sewage water. It turns out that detectable DNA signatures of individual plant and animal species remain behind even after they've been eaten, digested, excreted, and flushed down the toilet. He joins Host Flora Lichtman to describe his “Edible Atlas” project, the backend limitations of sewage analysis, and where the research might go.  Guest:  Dr. Lawrence David is an associate professor of molecular genetics and microbiology in the Center for Genomics and Computational Biology. He runs the Edible Atlas project at Duke University. Other episodes you may enjoy: You Share Your Gut Microbiome With Your Friends Dirty Diapers Reveal How Germy Babies' Microbiomes Are The transcript for this episode is available at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Long before cancer survivors organized into a movement, Hollywood had already shaped how Americans understood the disease. Films rarely used the word “cancer,” physicians often withheld diagnoses from patients, and the people who survived were almost nowhere to be found on screen.Recorded before The Cancer Mavericks: A History of Survivorship became a documentary series, this bonus conversation explores where the project first began. Matthew Zachary sits down with his mother, Roz Greenzweig, a retired educator and lifelong film enthusiast whose memories of classic cinema became an unexpected lens for understanding how cancer was portrayed throughout the twentieth century.Together, they revisit landmark films including Dark Victory, Love Story, and other iconic portrayals that reflected an era when cancer was treated as unspeakable, inevitable, and almost always fatal. Their conversation contrasts those carefully constructed Hollywood narratives with the lived reality of a family confronting a brain cancer diagnosis in 1995, revealing how popular culture both reflected and reinforced the fears surrounding the disease.The discussion also foreshadows many of the themes explored throughout the documentary series: the evolution of patient advocacy, the emergence of cancer survivorship, the role of caregivers, and the power of storytelling to influence public understanding. Before policy changed, before advocacy organizations grew into national movements, conversations like these were already challenging long-held assumptions about what cancer looked like and who had the right to tell its story.Consider this the prologue to The Cancer Mavericks. Before the movement found its history, it began with a family trying to make sense of the stories they had inherited.RELATED LINKSAmerican Cancer Society⁠National Cancer Institute⁠American Film Institute⁠ER (NBC)⁠50/50 (Official)⁠Chasing Life (ABC Family Archive)⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Questions? Email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Shayne Morris didn't stumble into the microbiome world — he inherited it. Now CEO of both Systemic Formulas and Alimentum Labs, Shayne's grandfather started the company back in 1984 as a healer studying Eastern, Polynesian, and South American medicine, and Shayne spent his career turning that legacy into hard science: how nature actually produces healing, and why the microbes living in and on us — which outweigh every other living thing on the planet combined — do more biochemical work than our own 23,000 genes ever could. In this episode, we get into herbal genomics (Shayne coined the term "herbalomics" back when he realized compounds like turmeric were directly switching genes on and off), why methylated vitamins were considered fringe in 2007 when Systemic started using them, and the surprisingly recent science connecting fungal overgrowth to childhood ADHD and eczema. We also break down the Holobiome Roadmap — Systemic's five-stage system designed to make gut and cellular health personalized without handing a patient fourteen different bottles and no instructions — and why compliance, not complexity, is usually what determines whether a protocol actually works. Along the way: the real story behind why doctors started washing their hands between autopsies and deliveries, and details on Systemic's NextGen event in Ogden, Utah (September 18–20), where Freddie will be speaking on sales as a role of service. Highlights: 00:00 - Introduction to Shane Morris and microbiome's significance 02:20 - Microbes as the foundational layer of health 05:05 - The weight of the microbiome on planetary health 07:01 - How microbes have been misunderstood and underappreciated 09:00 - The impact of diet and environment on microbiome diversity 11:07 - The immune system's development through microbial exposure 13:26 - The importance of personalized microbiome therapies 17:17 - From natural remedies to microbiome science and research 23:19 - Challenges in probiotic product selection and strain specificity 27:43 - Stool testing and genetic tools for microbiome insights 35:14 - Support strategies for aging microbiome health 43:41 - The Holobiome Roadmap: structure and application 50:09 - The influence of lifestyle and sleep on microbiome recovery 65:14 - Supporting neurological health through microbiome balance 70:45 - Upcoming event details and practitioner resources 73:39 - Practical advice for supplementing and maintaining microbiome health Connect with Shayne and Systemic Formulas https://systemicformulas.com/ Instagram: https://www.instagram.com/systemic_formulas/ Discount code: freddie10  Upgrade Your Wellness: LightPathLED: https://lightpathled.pxf.io/c/3438432/2059835/25794 Code: beautifullybroken Silver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD 30% off with Code: BEAUTIFULLYBROKEN MaxGen Labs: https://maxgenlabs.com/BEAUTIFULLYBROKEN CONNECT WITH FREDDIEWork with Me: https://www.beautifullybroken.world/biological-blueprintWebsite and Store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/freddie.kimmelYouTube: https://www.youtube.com/@beautifullybrokenworld Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Learn about the creation of the Kelnhofer Friesian Genomics Lab and Fenway's newest major health initiative, the Friesian DNA bank. We discuss what a DNA bank is, why the Friesian breed needs a dedicated long-term research resource, how this connects to megaesophagus and gastroparesis research, and what we hope the lab will make possible for the future of Friesian health.

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We're joined by first-time guest Lacey W. Heinsberg, PhD, RN, on this week's episode of the Faculty Factory Podcast to examine many of the ethical considerations surrounding the widespread use of generative AI tools (ChatGPT, Google Gemini, Claude, etc.). Dr. Heinsberg is Assistant Professor of Health Promotion & Development in the School of Nursing, and of Human Genetics in the School of Public Health, at the University of Pittsburgh. She also serves as Co-Director of the Genomics of Patient Outcomes HUB in the School of Nursing. It feels difficult to opt out of using generative AI without there being serious consequences to our careers, yet as we learn in today's episode, it's a deeply personal choice whether to use it and how much to use it. Personal Code of Conduct Dr. Heinsberg created her own personal code of conduct about using generative AI and discussed this in the interview today. Some of its themes include: "Enhance it, don't replace it" and staying aligned with her own institution's AI use policy. There is almost a certain slippery slope facing us all when it comes to an overreliance on generative AI. Writing is thinking, so if AI is writing for us, are we thinking more deeply? Is this harming our critical thinking? "When does trust but verify become ‘why bother using it at all?", she said. Broaching Tough Questions No one has all the answers to this, but it is important to be discussing this with your teams and to embrace these tough questions. Other recurring themes in this episode include: Authenticity.  Integrity.  Transparency (and where the line is between ghostwriting and flat-out generation of unoriginal text). If you're not sure where to get started on your code of conduct policies, or if you have any other questions, you can reach out to her directly via email: law145@pitt.edu.

India has finally approved a vaccine for dengue. This is significant because India, in the last five years alone, has recorded over 1 million cases and at least 1,500 deaths due to dengue. Dengue is hyperendemic in India, which makes it a huge public health challenge. A vaccine, in this context, could make a big difference. Named QDENGA, the new vaccine has been developed by Takeda Biopharmaceuticals, a Japanese pharma company. It is expected to be sold in India in the first half of 2027. How was this vaccine developed, how safe is it, how effective will it be in India, and can it prevent the frequent outbreaks of dengue that we've seen in recent years? Guest: Dr Gagandeep Kang, Director-Enterics, Diagnostics, Genomics and Epidemiology, Global Health at the Gates Foundation, Seattle Host: G Sampath, Social Affairs Editor, The Hindu Producer and editor: Jude Weston Learn more about your ad choices. Visit megaphone.fm/adchoices

0:00 The friend he hasn't seen since sixth grade 5:16 Angelina Jolie, BRCA, and the 20% nobody tells women about 18:23 What a cancer cell actually is - and why tumors evolve 26:31 How cancer actually kills you, and what a seizure is 32:14 The last cigarette: why he can't take the test every week 46:27 The best medicine in the world, and who can't get to it 1:03:23 Telling a family there's nothing left Noam hadn't seen Kenan Onel since high school in Ardsley, where Onel graduated first in the class and Noam, by his own account, drifted somewhere well below. Fifty years later Onel runs genetics and genomics at Roswell Park - the only comprehensive cancer center in all of western New York - and Noam has one thing he wants to ask him about. He's afraid of cancer. His grandfather died of it. His father died of it. He's taken the Grail blood test, it came back clean, and he wants to know why he can't just take it every week. What follows is part reunion and part interrogation. Onel explains what a cancer cell actually is, why tumors evolve like finches in the Galapagos, and what is physically happening to someone during a seizure. He explains how cancer kills - the mechanism, organ by organ. And he tells Noam that the test he's counting on just failed its biggest trial in the UK, which sets off the real argument of the hour: whether a guideline written for a population means anything at all to the one person sitting in the chair. Then, near the end, Noam asks how you tell a family there's nothing left to offer. The answer is the best thing in the episode. Also: the 20% of women who are high-risk and have never been told, the doctor who warned Noam that Pellegrino was bad for his son's bones, a scan booked by 4pm the next afternoon, and one entire podcast without mentioning Israel. Dr. Kenan Onel is Chief of the Division of Genetics and Genomics and Director of the Center for Precision Oncology and Cancer Prevention at Roswell Park Comprehensive Cancer Center. Live from the Table is the official podcast of the world-famous Comedy Cellar.

0:00 The friend he hasn't seen since sixth grade 5:16 Angelina Jolie, BRCA, and the 20% nobody tells women about 18:23 What a cancer cell actually is - and why tumors evolve 26:31 How cancer actually kills you, and what a seizure is 32:14 The last cigarette: why he can't take the test every week 46:27 The best medicine in the world, and who can't get to it 1:03:23 Telling a family there's nothing left Noam hadn't seen Kenan Onel since high school in Ardsley, where Onel graduated first in the class and Noam, by his own account, drifted somewhere well below. Fifty years later Onel runs genetics and genomics at Roswell Park - the only comprehensive cancer center in all of western New York - and Noam has one thing he wants to ask him about. He's afraid of cancer. His grandfather died of it. His father died of it. He's taken the Grail blood test, it came back clean, and he wants to know why he can't just take it every week. What follows is part reunion and part interrogation. Onel explains what a cancer cell actually is, why tumors evolve like finches in the Galapagos, and what is physically happening to someone during a seizure. He explains how cancer kills - the mechanism, organ by organ. And he tells Noam that the test he's counting on just failed its biggest trial in the UK, which sets off the real argument of the hour: whether a guideline written for a population means anything at all to the one person sitting in the chair. Then, near the end, Noam asks how you tell a family there's nothing left to offer. The answer is the best thing in the episode. Also: the 20% of women who are high-risk and have never been told, the doctor who warned Noam that Pellegrino was bad for his son's bones, a scan booked by 4pm the next afternoon, and one entire podcast without mentioning Israel. Dr. Kenan Onel is Chief of the Division of Genetics and Genomics and Director of the Center for Precision Oncology and Cancer Prevention at Roswell Park Comprehensive Cancer Center. Live from the Table is the official podcast of the world-famous Comedy Cellar.

What if curing a disease took a single treatment instead of a lifetime of pills, and the same technology could help cool the planet? In this episode, Dr. Bradley Ringeisen, Executive Director of the Innovative Genomics Institute (IGI) at UC Berkeley, takes us inside the CRISPR revolution. From the first FDA-approved sickle cell therapy to a custom cure that saved a baby's life in Philadelphia, to rice engineered to emit 60% less methane, Brad reveals how genome editing is reshaping medicine, climate, and food security alike. We dig into the science, the make-or-break "delivery" challenge, and the IGI's "CRISPR Commons" initiative, a bold plan to make genome editing equitably accessible worldwide.

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

How do you actually pick which heifers to keep? For many, selecting the top ones is easy, but it's those middle ones that are hard to choose between. For this week's guest, Geoff Hayes, the answer is genomics. Geoff and his wife Belinda started their Angus stud just 5 years ago, but began their genomic journey early, not wanting to pick bulls on looks alone from the very beginning. "I was hesitant just to go and pick them visually," Geoff explains. "We need to put some science into it."They began with a base genomic test across a random selection of purchased cattle, which showed them that they were fine for IMF, but needed to increase ribeye area, and that became the main basis of their early selection focus.Over time, that focus shifted. Rather than just chasing carcass traits, they started looking for sires out of cow families with longevity in the background. This introduced more of a focus on the maternal and stayability traits. Geoff still tests his own weaners before deciding which ones to keep and that same mindset is now extending to heifers, with Geoff part of MLA's heifer PDS project. The project involves genotyping heifers, alongside visual measurements to help guide replacement decisions. This project is ongoing, and we will have results to share in the coming years. Mark and Geoff finish by talking about where the beef industry is headed with record property and beef values, as well as the possibilities of new technology just around the corner.Optimised Heifer Selection is a Producer Demonstration Site (PDS) project funded by Meat & Livestock Australia and facilitated by neXtgen Agri. Geoff Hayes is a core producer demonstration site for this project. If you would like to learn more about this PDS project, you can visit the Heifer Selection Hub page or contact: Georgia Pugh, neXtgen Agri M: +61 408 947 488 E: georgia@nextgenagri.comHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, Heiniger Australia and New Zealand, and ProWay Livestock Equipment. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out the MSD range HERECheck out Allflex products HERECheck out Heiniger's product range HERECheck out ProWay's product range HERE

In this episode we speak with Alon Goren from UC San Diego about his work at the intersection of genomic technology development and chromatin biology. We discuss how his lab studies how the epigenome is regulated, how disruption of that regulation contributes to disease, and how technology can be improved to make results more robust and reproducible. We talk about his early interest in biology, how that developed through medical research training, and how a molecular biology lab shaped the direction of his career. He explains how curiosity about how cells and organisms work led him toward genomics and chromatin research. We then discuss several methods from his career, including early direct sequencing approaches for small amounts of DNA and RNA, ChIP-based methods for chromatin regulators, and work on improving ChIP-seq workflows. He explains why antibody choice matters, why monoclonal antibodies can improve reproducibility, and how automation helped scale the process. We also cover his work on spike-in normalization, including the risks of using exogenous chromatin incorrectly and the need for better safeguards in genome-wide comparisons. He describes a newer approach that uses two spike-ins to provide multiple checks on normalization. Finally, we discuss his work on short tandem repeats, zebrafish heart regeneration, and SIRT6-related polymerase pausing, as well as a newer platform that converts molecular interactions into sequencing-readable barcodes. He closes by stressing the importance of validation, careful protocol design, and methods that can be used reliably by multiple people. References Ram, O., Goren, A., Amit, I., Shoresh, N., Yosef, N., Ernst, J., Kellis, M., Gymrek, M., Issner, R., Coyne, M., Durham, T., Zhang, X., Donaghey, J., Epstein, C. B., Regev, A., & Bernstein, B. E. (2011). Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell, 147(7), 1628–1639. https://doi.org/10.1016/j.cell.2011.09.057 Busby, M., Xue, C., Li, C., Farjoun, Y., Gienger, E., Yofe, I., Gladden, A., Epstein, C. B., Cornett, E. M., Rothbart, S. B., Nusbaum, C., & Goren, A. (2016). Systematic comparison of monoclonal versus polyclonal antibodies for mapping histone modifications by ChIP-seq. Epigenetics & chromatin, 9, 49. https://doi.org/10.1186/s13072-016-0100-6 Patel, L. A., Cao, Y., Mendenhall, E. M., Benner, C., & Goren, A. (2024). The Wild West of spike-in normalization. Nature biotechnology, 42(9), 1343–1349. https://doi.org/10.1038/s41587-024-02377-y Ben-Yair, R., Butty, V. L., Busby, M., Qiu, Y., Levine, S. S., Goren, A., Boyer, L. A., Burns, C. G., & Burns, C. E. (2019). H3K27me3-mediated silencing of structural genes is required for zebrafish heart regeneration. Development (Cambridge, England), 146(19), dev178632. https://doi.org/10.1242/dev.178632 Patel, L., Cao, Y., Xu, T., Modolo, E., Dishon, T., Zhang, L., Mendenhall, E., Heinz, S., Simon, I., Benner, C., & Goren, A. (2025). Improved spike-in normalization clarifies the relationship between active histone modifications and transcription. Genomics. https://doi.org/10.1101/2025.11.25.690627 Xu, T., Wang, J., Shin, Y., Cao, Y., Zhang, L., Modolo, E., Dishon, T., Fisher, J., Norton, M., Fry, C. J., Farjoun, Y., Mendenhall, E., Heinz, S., Benner, C., & Goren, A. (2026). Multiplexed measurements of protein-protein interactions and protein abundance across cellular conditions using Prod&PQ-seq. Genomics. https://doi.org/10.64898/2026.01.01.697286 Related Episodes Taking ChIP from Yeast to ENCODE to Enable Genome-Wide Regulatory Protein Mapping (Peggy Farnham) Comparing CUT&Tag to ENCODE ChIP-Seq in Alzheimer's Disease Samples (Sarah Marzi) Chromatin Profiling: From ChIP to CUT&RUN, CUT&Tag and CUTAC (Steven Henikoff) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

Julia is a Senior Research Scientist at Bigelow Laboratory, where she has been working on ocean science research since 2016. Her current research aims to characterize the diversity and roles of marine viruses and microbes in order to better understand their activity within climate relevant ecosystems, such as the rapidly warming Gulf of Maine and large marine oxygen minimum zones. Julia was one of this year's 5 Minute Genius speakers at the 2026 Maine Science Festival. The New York Times featured Julia's work in 2020: https://www.nytimes.com/2020/09/24/science/virus-eaters-protists.html. This conversation was recorded in May 2026.   ~~~~~The Maine Science Podcast is a production of the Maine Discovery Museum. It is recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle. The Discover Maine theme was composed and performed by Nick Parker. To support our work: https://www.mainediscoverymuseum.org/donate. Find us online:Maine Discovery MuseumMaine Discovery Museum on social media: Facebook Instagram LinkedIn Bluesky YouTubeMaine Science Podcast on social media: Facebook Instagram YouTubeMaine Science Festival on social media: Facebook Instagram LinkedIn YouTube© 2026 Maine Discovery Museum

Hormone optimization goes beyond testosterone and estrogen. In this episode of the Optimization Academy Podcast, Dr. Greg Jones talks with Ashley Madsen, PA-C, about why symptoms like fatigue, brain fog, low libido, weight changes, poor recovery, and perimenopause concerns often need a deeper, more personalized approach.They discuss why testosterone levels are dropping in younger men, why many women's hormone symptoms are dismissed or misunderstood, and how stress, sleep, toxins, lifestyle, body composition, and metabolic health can affect hormone balance. Ashley also breaks down common misconceptions around testosterone therapy, estrogen, progesterone, peptide therapy, genomics, and longevity medicine.If you've been searching for answers around low testosterone, perimenopause, fatigue, brain fog, weight resistance, hormone therapy, or recovery, this episode offers a practical look at what may actually be driving those changes, and why symptoms, labs, lifestyle, and personalized care all matter.

In this explainer episode, we've asked Ella Davyson, Genomics Data Scientist, to explain the meaning of the term genomics. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. [00:00:00] Florence: What is genomics? My name is Florence Cornish, and today I'm joined by Ella Davyson, who is a genomics data scientist here at Genomics England, and she is here to explain the topic in much more detail So, Ella, we obviously both work at Genomics England. This podcast is called Genomics 101, so I guess it's fitting that we have an episode dedicated to explaining the term 'genomics'. [00:00:26] But before we get into that, I think it would be good if you could first explain what we mean by the term 'genome'. [00:00:32] Ella: Thanks, Florence. The genome is, essentially you can think of it like a manual booklet, or instructions that the body uses in how to grow, survive, and function, and this is a manual that's in every single cell within our body, and it tells our cells exactly how to divide, how to survive. [00:00:54] For example, the genome in the pancreas, in pancreatic cells will tell those cells how to produce proteins such as insulin that we need to control our blood sugar. And also, the genome within our eye cells will tell the cells how to generate photoreceptors to enable us to see. So the genome is essentially like the ultimate guide that our body uses to tell it how to create everything that we need to survive going forwards. [00:01:25] Florence: So then, what do we mean by the term 'genomics'? [00:01:30] Ella: So, genomics is essentially the study of the entire human genome. So we study its structure and also how it functions, in terms of how is this instruction manual being read by the body, and how does that result in healthy human beings that we see today. [00:01:48] Florence: So when we're talking about studying DNA, lots of our listeners might have heard the term 'genetics', which kind of also refers to the study of DNA and genes, so it might be a little bit confusing. [00:01:58] So what's the difference between the two? What's the difference between genetics and genomics? [00:02:04] Ella: So genetics is specifically the study of genes in the genome, and genes are part of the instruction manual, that specifically tell the body to produce a certain thing. So, in our insulin example, there is an INS gene, so, which is the gene in the genome or the instruction manual that specifically tells the cells to make insulin and to produce this product. [00:02:30] There are many different genes in our genome, and genetics is the study of all of these. In contrast, genomics is the study of the entire instruction manual altogether, so that includes all of the genes in genetics and also everything else in the manual. So, genetics is limited to the study of these parts of the manual that clearly encode certain proteins or products such as insulin. Genomics is the study of everything all at once, everything under the bathroom sink. So yeah, the confusion I think can arise a lot because historically when we first started looking at DNA and researching genetics, we didn't have the technology to look at the whole genome all at once, and with older sequencing technologies we would focus on particular genes that we knew important for certain diseases. [00:03:19] So in diabetes, for example, they would instead specifically look at the insulin gene and see how does this influence diabetes, rather than looking at the entire instruction manual at once. Nowadays, we do have that technology, and that is what we do here at Genomics England, just use that to look at the entire genome rather than specific subsets of the genome, so specific genes. [00:03:45] We can look at everything in its entirety. So, you can kind of think of genomics as a much broader, more complete study of genetics. [00:03:56] Florence: So speaking of genomic testing, I don't know if you saw, but in the government's 10-year Health Plan that they published last year, they predicted that genomics could play a role in up to 50% of healthcare interactions. [00:04:08] Could you tell me a bit about why genomics is important in healthcare? [00:04:12] Ella: So that's a really exciting point, and I think one that we should be all striving towards. So, genomics can play a role in healthcare in so many different ways. I think before going into each of them, it's kind of maybe important just to illustrate that our genomes between two, two people are 99.9% the same. [00:04:38] So we're both humans. We are both the same species. There is 0.1% difference between two people's genomes, and those differences underlie all the uniqueness that makes a person a unique individual. [00:04:54] So personality, appearance and also risk to different health and disease outcomes. So that is where the role of genomics can come in, is to understand how the differences between people and their genetic makeup can influence maybe their risk for being more predisposed to developing a condition. Conditions such as Cystic Fibrosis or Huntington's disease that are specifically caused by genetic variants or mutations in genes that directly cause the condition. So it's a bit more maybe obvious, if you like, about how studying genetics in those, in those conditions can directly inform on how they arise, potential ways that we can better treat them. [00:05:52] So another way that genomics can be used in healthcare is through screening. So this is being piloted at the moment in the Generation Study by Genomics England which is applying whole genome sequencing to newborn babies to look for a range of conditions which are caused by genetic changes, all of which are treatable. [00:06:13] But importantly, screening will enable clinicians and families to know about these conditions much earlier and start life-changing treatment much, much sooner. So this is kind of already beginning to be, I think it will be showcased with this study in the next couple of years and the power of this in healthcare, I think can't really be overestimated. [00:06:40] Florence: And finally, just to finish off, is there anything coming up in the field of genomics that you're especially excited about? [00:06:48] Ella: There are loads of different things that I'm excited about in the field of genomics. I think probably maybe one that's most kind of relevant to clinical care is the possibility of doing more personalised medicine with treatments. [00:07:05] Often, at the moment, we majority have kind of one treatment for all when treating certain conditions, and sometimes these treatments aren't tolerated well by some people, and also some of these treatments just don't work well in some people as well. Sometimes there's a clear reason for these things, but more often than not, it's not entirely clear why some people might benefit more for some treatments or some people don't respond or don't react well to some treatments as well. [00:07:35] And understanding more, so there's a whole field about how genomics interacts with drugs and medicines, which is called pharmacogenomics, and its aim is to understand which medicine might be most effective or well-tolerated in certain people based on their genetics. And I think that will be kind of life-changing as well for some people, who are suffering from diseases where the medication is either not effective enough or is also affecting their quality of life. [00:08:10] Florence: Mm-hmm. [00:08:10] Ella: Because that is a whole other part of it as well is that sometimes these treatments for certain conditions are really hard to tolerate. [00:08:19] Other things that I'm excited about are just the technologies that are coming out at the moment mean that we can measure and understand a whole lot more about genomics than we used to be. So now we can say this gene is influencing this disease, but sometimes, you know, it's more complicated, and we now have the technology to measure all sorts of different things, so how our environment can influence our genes and how our genes react with each other. [00:08:57] So we're just getting, we're getting able to look at more and more, and I think we'll expand our understanding in a lot of conditions that unfortunately aren't very simple. [00:09:12] Florence: Well, I think we'll finish there. Thank you so much, Ella, for coming on and for taking the time to explain genomics to us. [00:09:18] Ella: Thank you, Florence. Thanks so much for inviting me, and it was a pleasure to be on the podcast today. [00:09:23] Florence: If you want to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Joanne Armstrong, MD, Vice President and Chief Medical Officer, Women's Health and Genomics, CVS Health, discusses how CVS Health is improving access, affordability, and personalized care for women through innovative care delivery models, data-driven strategies, and benefits designed to meet women's evolving health needs.

"Your doctor doesn't live inside your body. AI doesn't live in your body. Influencers don't live in your body. Only you live there."What if the future of medicine isn't about treating disease, but empowering people to take ownership of their health long before illness appears?In this compelling conversation, Dr. Lara Varden sits down with renowned physician, author, and longevity expert Dr. Erika Schwartz to discuss a lifetime spent challenging conventional medicine and advocating for personalized, preventive healthcare.Dr. Schwartz is a board-certified internist, entrepreneur, best-selling author, and nationally recognized leader in hormone health and longevity medicine. For more than three decades, she has championed personalized, preventive care — long before it became mainstream. She is the founder of Evolved Science and ESHealth, where she has been a pioneer in the use of bioidentical hormone therapy, focusing on restoring vitality, optimizing healthspan, and redefining how we approach aging. Dr. Schwartz has authored eight best-selling books, including The Hormone Solution and The Intimacy Solution, helping bring conversations about hormone balance and quality of life into the medical mainstream. Her work has appeared in major publications such as The New York Times, The Wall Street Journal, Vogue, Town & Country, and The New York Post, and she is a frequent media contributor across television and international podcasts. She is also a distinguished faculty member of A4M — the world's leading longevity and functional medicine organization — where she hosts the widely followed Redefining Medicine podcast. Drawing from more than 40 years of clinical experience, Dr. Schwartz shares her journey from emergency medicine physician to one of the earliest pioneers of hormone optimization, functional medicine, and healthy aging. She explores why modern healthcare often focuses on disease instead of wellness, the truth about hormone replacement therapy, the importance of patient empowerment, and how genetics can help personalize health decisions.Tune in and realize how longevity isn't just about living longer, it's about living better.If you wish to learn more from Dr. Erika Schwartz, you can do so through the following links:Visit her website for Evolved Science at https://www.eshealth.com/Instagram: @eshealth and @drerikaschwartzFacebook: https://www.facebook.com/evolvedscience/______________________________________________________Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram: @dnatalkspodcastThe DNA Company Instagram: @thednacoThe DNA Company's Official Tiktok Account: @thednaco3Medical Disclaimer:  The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.

In this episode, Joanne Armstrong, MD, Vice President and Chief Medical Officer, Women's Health and Genomics, CVS Health, discusses how CVS Health is improving access, affordability, and personalized care for women through innovative care delivery models, data-driven strategies, and benefits designed to meet women's evolving health needs.

Misha Glenny and guests discuss the earliest evidence we have of the existence of trees and how even plants we might have on windowsills or as vegetables in gardens can and do, in the right conditions, evolve into trees. Since their emergence around 400 million years ago after low lying plants started to develop stronger stems and grow taller and more upright, trees have transformed our planet, so creating ecosystems, altering the atmosphere and setting the stage for the world as we know it today. With Jenny McElwain 1711 Chair of Botany at Trinity College Dublin and Director of Trinity Botanic GardensChristopher Berry Senior Lecturer in Earth and Environmental Sciences at Cardiff UniversityAndBill Baker Senior Researcher at the Royal Botanic Gardens, KewProduced by Conor GarrettReading list:David Beerling: The Emerald Planet: How Plants Changed Earth's History (Oxford University Press, 2008)C.M. Berry, ‘Palaeobotany: The Rise of the Earth's Early Forests' (Current Biology 29, 2019)Christopher M. Berry and John E.A. Marshall, ‘Lycopsid forests in the early Late Devonian paleoequatorial zone of Svalbard' (Geology 43:12, 2015)N.S. Davies, W.J. McMahon and C.M. Berry, ‘Earth's earliest forest: fossilized trees and vegetation-induced sedimentary structures from the Middle Devonian (Eifelian) Hangman Sandstone Formation, Somerset and Devon, SW England' (J. Geol. Soc. 181, 2024)P. Geisen and C.M. Berry, ‘Reconstruction and Growth of the Early Tree Calamophyton (Pseudosporochnales, Cladoxylopsida) Based on Exceptionally Complete Specimens from Lindlar, Germany (Mid-Devonian): Organic Connection of Calamophyton Branches and Duisbergia Trunks' (International Journal of Plant Sciences 174 (4), 2013) A. Groover and Q. Cronk (eds), Comparative and Evolutionary Genomics of Angiosperm Trees: Plant Genetics and Genomics (Crops and Models, vol 21. Springer, 2017), especially ‘The Evolution of Angiosperm Trees: From Palaeobotany to Genomics' by Q.C.B. Cronk and F. ForestJennifer McElwain, Marlene Hill Donnelly, and Ian Glasspool, Tropical Arctic: Lost Plants, Future Climates, and the Discovery of Ancient Greenland (University of Chicago Press, 2021)Harriet Rix, The Genius of Trees: How Trees Mastered the Elements and Shaped the World (Vintage, 2026)W.E. Stein et al., ‘Mid-Devonian Archaeopteris roots signal revolutionary change in earliest fossil forests' (Current biology, 30:3, 2020) pp.421-431William E. Stein, Christopher Mark Berry, Linda VanAller Hernick and Frank Mannolini ‘Surprisingly complex community discovered in the mid-Devonian fossil forest at Gilboa' (Nature 483, 7387, 2012) Max Telford, The Tree of Life: Solving Science's Greatest Puzzle (John Murray, 2026)K.J. Willis, J.C. McElwain, The Evolution of Plants (Oxford University Press, 2014)James Woodford, The Wollemi Pine: The Incredible Discovery of a Living Fossil from the Age of the Dinosaurs (The Text Publishing Company, 2005)Alexandre R. Zuntini et al, ‘Phylogenomics and the rise of the angiosperms' (Nature vol. 629, April 2024) Spanning history, religion, culture, science and philosophy, In Our Time from BBC Radio 4 is essential listening for the intellectually curious. In each episode, host Misha Glenny and expert guests explore the characters, events and discoveries that have shaped our world.

Jeremy Lipkowitz has degrees in Genetics and Genomics. After overcoming addiction and depression through meditation in his early twenties, he left academia and his PhD Program at Duke University to help others find similar breakthroughs.   Jeremy's journey led him to spend time as a Buddhist monk in Asia, deepening his understanding of mindfulness and inner freedom. His work focuses on helping high-achieving men break free from destructive patterns like porn and sex addiction to build lives of purpose, discipline, and fulfillment.   0.00:    Introduction 3.00:    How Buddhist Philosophy changed Jeremy's life 13.00:  Why it's a fools errand to think that a singular outcome will lead to true happiness 17.00:  The philosophy of Buddhism 21.00:  The difficulty and benefits of a 10 day silent retreat 27.00:  The Bliss of Blamelessness 32.00:  The misconceptions of Buddhism 39.00:  How to enjoy your life according to the seasons 45.00:  Why a disciplined mind brings happiness 49.00:  Overcoming Porn Addiction and the erosion of dopamine 57.00:  The difficulties of dating in the West 1.03.00:  How to get through tough periods through having positive habits 1.07.00:  Importance of communities and connection through recovery   1.12.00:  The amazing quality of life in Thailand 1.22.00:  Contact Jeremy on his podcast   Follow Jeremy on IG: @jeremylipkowitz Podcast: Unhooked (on all major platforms)   Until next time, love and good vibes.  Podcast Website: https://enterthelionheart.com/ Check out the latest episode here: Apple Podcast: https://podcasts.apple.com/us/podcast/enter-the-lionheart/id1554904704 Spotify: https://open.spotify.com/show/4tD7VvMUvnOgChoNYShbcI

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The current Ebola outbreak in the Democratic Republic of the Congo and neighboring Uganda is caused by the Bundibugyo virus. There's no specific treatment or vaccine for this strain, unlike the more common Zaire strain that caused the 2014 outbreak.  Molecular biologist Christian Happi has dedicated his career to improving genomic sequencing capabilities and virus monitoring across the continent of Africa. He joins Flora to discuss the challenges of the current outbreak and his vision for better disease surveillance.  Guest: Dr. Christian Happi is a distinguished professor at Redeemer's University and runs the Institute of Genomics and Global Health in Nigeria. Other episodes you may enjoy: Inside the Nebraska quarantine facility responding to hantavirus Can ‘Suggestion-Box Science' Make Public Health More Useful? Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.